Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

Nature Reviews Endocrinology is a premier journal published by NATURE PORTFOLIO, providing comprehensive and critical reviews in the rapidly evolving field of endocrinology. Established to foster advanced understanding, it has become a vital resource for researchers, professionals, and students alike. With an impressive impact factor and a prominent ranking of Q1 in both Endocrinology and Endocrinology, Diabetes, and Metabolism categories for 2023, the journal is recognized for its high-quality research dissemination, evidenced by its rankings of #2 out of 244 in Medicine and #2 out of 128 in Biochemistry, Genetics, and Molecular Biology. Spanning the years from 2009 to 2024, it focuses on publishing cutting-edge information that shapes current scientific knowledge and clinical practices. The journal offers open access options, ensuring greater visibility and reach for its articles. Located in Germany, this journal remains at the forefront of endocrinology research, significantly contributing to the understanding of hormonal functions and their implications on health. Discover the latest advancements and insights by exploring Nature Reviews Endocrinology.

Expert Review of Endocrinology & Metabolism is a premier journal dedicated to advancing the field of endocrinology and metabolism, published by Routledge Journals, Taylor & Francis Ltd, in the United Kingdom. With a robust focus on the latest research, innovative treatments, and clinical practices, this journal serves as an essential resource for healthcare professionals, researchers, and students seeking to stay abreast of developments in diabetes, obesity, thyroid disorders, and other endocrine-related conditions. Achieving a commendable Q2 status in Endocrinology, Diabetes, and Metabolism in the 2023 ranking, Expert Review of Endocrinology & Metabolism holds strong standing with an impressive Scopus rank, placing it at the 53rd percentile among its peers. The journal embraces a comprehensive approach, offering critical reviews, original research articles, and insights on emerging trends and technologies in the field. Although not an open-access journal, it provides extensive access options for subscribers and institutions, encouraging ease of dissemination and academic engagement. Through its commitment to high-quality content, Expert Review of Endocrinology & Metabolism remains pivotal for professionals aiming to enhance their understanding and practice in this vital area of medicine.

The JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, published by Walter de Gruyter GmbH, is a reputable peer-reviewed journal dedicated to advancing the field of pediatric endocrinology and metabolism. Since its inception in 1985, this journal has become a vital resource for professionals and researchers, providing insights into the latest advancements, clinical practices, and foundational research in the care of children with endocrine disorders. With a noted Q3 ranking in Endocrinology, Diabetes and Metabolism, and a robust focus on Pediatrics, Perinatology, and Child Health, it addresses important topics such as hormonal imbalances and metabolic syndromes in young populations. Despite its non-open access status, it continues to play an essential role in bridging the knowledge gap within our understanding of children's health and disease, contributing significantly to the progress in this specialized field.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

Journal of Endocrinology Metabolism and Diabetes of South Africa, published by Routledge Journals, Taylor & Francis Ltd, serves as a vital platform for advancing research and knowledge dissemination in the fields of endocrinology, metabolism, and diabetes. Since its transition to Open Access in 2012, it has enabled greater accessibility to crucial findings and data, broadening its reach to researchers, practitioners, and students alike. Though its coverage in Scopus was discontinued in 2018, the journal continues to play an important role in fostering discourse in the medical community, as evidenced by its ranking within the 19th and 16th percentiles for Internal Medicine and Endocrinology, diabetes and metabolism, respectively. With its commitment to addressing pressing health issues in South Africa and beyond, this journal remains an invaluable resource for those seeking to understand and tackle the complexities of metabolic diseases.

CLINICAL ENDOCRINOLOGY, published by Wiley, is a premier journal in the field of endocrinology, providing a vital platform for the dissemination of cutting-edge research and advancements in the diagnosis and treatment of endocrine disorders. Since its inception in 1972, this prestigious journal has maintained its commitment to excellence with its scope encompassing diverse areas within endocrinology, diabetes, and metabolism, evidenced by its impressive ranking in the Q2 quartile for these categories as of 2023. With a growing impact factor, it serves as a leading reference for researchers and healthcare professionals dedicated to improving patient outcomes. Although the journal does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital research reaches an expansive audience. Its robust focus on clinical applications makes CLINICAL ENDOCRINOLOGY an essential resource for anyone involved in the evolving field of endocrinology, thereby underscoring its importance in shaping future research and practice in healthcare.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.